Literature DB >> 18774533

Natural history of severe ulcerative colitis in a community-based health plan.

James Allison1, Lisa J Herrinton, Liyan Liu, Jenny Yu, James Lowder.   

Abstract

BACKGROUND & AIMS: We sought to evaluate long-term outcomes of patients with severe ulcerative colitis (UC) after their first hospitalization for the disease.
METHODS: A cohort of 656 patients hospitalized for UC during 1996 to 2004 was followed up for 9 years through 2004. Time-to-event was estimated using actuarial methods, and the proportions of those under follow-up evaluation who experienced outcomes at month 3, year 1, and year 5 were determined. Outcome measures studied were time to subsequent colectomy, rehospitalization for inflammatory bowel disease, and restarting steroid medication. We also used survival analysis to evaluate whether patient characteristics predicted the risk of rehospitalization and colectomy.
RESULTS: Among 656 patients initially hospitalized for severe UC, 20% (N = 129) underwent colectomy during their initial hospitalization. Of the remaining 527, a total of 95% (N = 498) were discharged on a steroid taper. At 1 year after discharge, 29% of those remaining under observation were rehospitalized for UC, and an additional 10% required colectomy. At 1 and 5 years after discharge, 34% and 26% received at least a 90-day supply of steroid in the preceding 9 months. Risk of rehospitalization and colectomy were unrelated to the patient's age, sex, or race/ethnicity.
CONCLUSIONS: The risk for colectomy in patients hospitalized for the first time with severe UC is 20%. In the 3 months after hospitalization the risk for colectomy is 6%. After that, risks appear to decrease proportionate to the time since initial hospitalization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774533     DOI: 10.1016/j.cgh.2008.05.022

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  17 in total

1.  Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis.

Authors:  Orlaith B Kelly; Morgan Rosenberg; Andrea D Tyler; Joanne M Stempak; A Hillary Steinhart; Zane Cohen; Gordon R Greenberg; Mark S Silverberg
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

2.  IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function.

Authors:  Amanda Waddell; Jefferson E Vallance; Preston D Moore; Amy T Hummel; David Wu; Shiva K Shanmukhappa; Lin Fei; M Kay Washington; Phillip Minar; Lori A Coburn; Susumu Nakae; Keith T Wilson; Lee A Denson; Simon P Hogan; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

3.  Hormonal contraception and the development of autoimmunity: A review of the literature.

Authors:  William V Williams
Journal:  Linacre Q       Date:  2017-08-18

4.  Sex Differences in Experimentally Induced Colitis in Mice: a Role for Estrogens.

Authors:  Janka Bábíčková; Ľubomíra Tóthová; Eva Lengyelová; Anastázie Bartoňová; Július Hodosy; Roman Gardlík; Peter Celec
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

5.  Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis.

Authors:  Eleonora Scaioli; Alessandro Sartini; Elisa Liverani; Richard John Digby; Giampaolo Ugolini; Giancarlo Rosati; Gilberto Poggioli; Davide Festi; Franco Bazzoli; Andrea Belluzzi
Journal:  Dig Dis Sci       Date:  2017-01-21       Impact factor: 3.199

Review 6.  Use of Biologics in Pouchitis: A Systematic Review.

Authors:  Hans H Herfarth; Millie D Long; Kim L Isaacs
Journal:  J Clin Gastroenterol       Date:  2015-09       Impact factor: 3.062

7.  Assessment of Sex Differences for Treatment, Procedures, Complications, and Associated Conditions Among Adolescents Hospitalized with Crohn's Disease.

Authors:  Jennifer L Dotson; Josh B Bricker; Michael D Kappelman; Deena Chisolm; Wallace V Crandall
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

8.  STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines.

Authors:  Michael J Rosen; Rupesh Chaturvedi; M Kay Washington; Lindsay A Kuhnhein; Preston D Moore; Scott S Coggeshall; Elizabeth M McDonough; Jörn-Hendrik Weitkamp; Amar B Singh; Lori A Coburn; Christopher S Williams; Fang Yan; Luc Van Kaer; R Stokes Peebles; Keith T Wilson
Journal:  J Immunol       Date:  2013-01-09       Impact factor: 5.422

9.  Total colectomy for ulcerative colitis in children: when are we operating?

Authors:  Jarod P McAteer; Cindy Larison; Ghassan T Wahbeh; Matthew P Kronman; Adam B Goldin
Journal:  Pediatr Surg Int       Date:  2013-04-10       Impact factor: 1.827

Review 10.  How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.

Authors:  Parambir S Dulai; Siddharth Singh; Niels V Casteele; Brigid S Boland; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.